查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654345

非病毒基因傳遞技術市場規模、佔有率、趨勢分析報告：按模式、應用、最終用途、地區和細分市場預測，2025-2030 年

Non-viral Gene Delivery Technologies Market Size, Share & Trends Analysis Report By Mode (Chemical, Physical), By Application (Research, Therapeutics), By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

非病毒基因傳遞市場的成長與趨勢

根據 Grand View Research, Inc. 的最新報告，全球非病毒基因傳遞技術市場規模預計到 2030 年將達到 71.1 億美元，預測期內（2025-2030 年）的複合年成長率為 12.29%。

該市場的成長是由基因治療和研究中對安全、可擴展且具有成本效益的病毒載體替代品的需求不斷成長所推動的。與病毒方法不同，脂質奈米顆粒 (LNP)、聚合物和電穿孔等非病毒技術具有低免疫抗原性且製造複雜性降低。這些特性使它們非常適合大規模應用，例如基於 mRNA 的疫苗和基於 CRISPR/Cas9 的基因編輯療法。 Moderna 和 Pfizer-BioNTech 的 mRNA COVID-19 疫苗的成功進一步證明了非病毒遞送系統的潛力，並刺激了全球對這一領域的投資。

奈米技術和生物材料的進步進一步加速了這一領域的創新。奈米粒子、脂質體和混合載體正在進行最佳化，以提高轉染效率和標靶遞送。隨著癌症、罕見遺傳疾病和心血管疾病等慢性病的發病率上升，對有效、精準治療方案的需求呈指數級成長。允許傳遞大劑量基因和重複給藥的非病毒技術對於解決這些未滿足的醫療需求至關重要。此外，它們在體外研究和體內治療應用方面的多功能性使其在生物技術、製藥和學術機構中廣泛應用。

政府對基因治療研究的資助和私人投資的增加也是市場成長的主要驅動力。雖然北美和歐洲等地區在研發方面處於領先地位，但中國和印度等亞太新興國家隨著生物技術基礎設施和法律規範的發展也迅速進步。此外，生物技術公司和學術機構之間的合作正在推動創新並擴大非病毒遞送解決方案的可及性，從而確保它們在快速發展的基因治療領域的重要性。

非病毒基因傳遞技術市場報告重點

  • 預計化學品行業將在 2024 年佔據最大的收益佔有率，並且預計在預測期內將呈現最快的成長率。非病毒基因傳遞技術的化學模式是由對高效、安全和可擴展的基因傳遞系統日益成長的需求所驅動。
  • 由於對研究基因功能、表達和調控的多功能、高效且經濟高效的工具的需求不斷成長，研究市場在 2024 年佔據了最大的收益佔有率。
  • 根據最終用途，研究和學術機構部門將在 2024 年佔據最大的收益佔有率，為 48.11%，預計在預測期內將以最快的複合年成長率成長。這種成長是由對研究基因功能、表達和修飾的可靠、高效且經濟的方法的需求不斷成長所推動的。
  • 到 2024 年，北美地區將佔據全球市場的主導地位，市場佔有率為 41.25%。該地區擁有先進的醫療基礎設施，能夠迅速採用創新的基因轉移技術。人們對精準醫療的興趣日益濃厚，以及針對遺傳疾病的臨床測試的增加進一步推動了市場的成長。此外，政府對基因組研究的措施和資助也促進了非病毒遞送技術的使用增加。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL 分析
    • COVID-19影響分析

第4章模式業務分析

  • 模式細分儀表板
  • 非病毒基因傳遞技術市場：模式變異分析
  • 2018 年至 2030 年非病毒基因傳遞市場規模及趨勢分析（按模式）
  • 化學
    • 2018 年至 2030 年化學品市場估計與預測
    • LNP
    • 聚合物
    • 其他
  • 身體的
    • 2018 年至 2030 年實體市場估計與預測
    • 電穿孔
    • 顯微注射
    • 其他

第5章 應用業務分析

  • 應用程式細分儀表板
  • 非病毒基因傳遞技術市場：應用趨勢分析
  • 2018 年至 2030 年非病毒基因傳遞市場規模及應用趨勢分析
  • 研究
    • 2018 年至 2030 年研究市場估計與預測
  • 治療
    • 2018 年至 2030 年治療市場估計與預測
    • 基因治療
    • 細胞療法
    • 疫苗

第6章 最終用途業務分析

  • 最終用途細分儀表板
  • 非病毒基因傳遞技術市場：最終用途變異分析
  • 非病毒基因傳遞技術市場規模和趨勢分析（按最終用途），2018 年至 2030 年
  • 生物技術和生物製藥公司
    • 2018 年至 2030 年生物技術和生物製藥公司市場估計和預測
  • 研究和學術機構
    • 2018 年至 2030 年研究與學術機構市場估計與預測
  • 其他
    • 2018 年至 2030 年其他市場估計與預測

第7章。

  • 區域控制面板
  • 2024 年和 2030 年市場規模、預測和趨勢分析
  • 北美洲
    • 2018 年至 2030 年北美非病毒基因傳遞技術市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018 至 2030 年歐洲非病毒基因傳遞技術市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018 年至 2030 年亞太地區非病毒基因傳遞技術市場
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 拉丁美洲非病毒基因傳遞技術市場，2018-2030 年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲非病毒基因傳遞技術市場，2018-2030 年
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 公司分類
  • 戰略地圖
  • 2024 年企業市場分析
  • 公司簡介/上市公司
    • Thermo Fisher Scientific Inc.
    • GenScript
    • Danaher
    • Merck KGaA
    • Bio-Rad Laboratories
    • Altogen Biosystems
    • Lonza
    • Sonidel
    • SIRION BIOTECH GmbH
    • Innovative Cell Technologies, Inc.
Product Code: GVR-4-68040-497-6

Non-viral Gene Delivery Technologies Market Growth & Trends:

The global non-viral gene delivery technologies market size is anticipated to reach USD 7.11 billion by 2030 and grow at a CAGR of 12.29% from 2025 to 2030 during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is driven by the growing demand for safe, scalable, and cost-effective alternatives to viral vectors in gene therapy and research. Unlike viral methods, non-viral technologies such as lipid nanoparticles (LNPs), polymers, and electroporation offer lower immunogenicity and reduced manufacturing complexities. These attributes make them highly suitable for large-scale applications, including mRNA-based vaccines and CRISPR/Cas9-based gene editing therapies. The success of mRNA COVID-19 vaccines by Moderna and Pfizer-BioNTech further validated the potential of non-viral delivery systems, spurring global investment in this sector.

Advancements in nanotechnology and biomaterials are further accelerating innovation in the field. Nanoparticles, lipoplexes, and hybrid carriers are being optimized for enhanced transfection efficiency and targeted delivery. With the rising prevalence of chronic diseases, including cancer, rare genetic disorders, and cardiovascular conditions, the need for effective and precise therapeutic solutions has surged. Non-viral technologies, with their ability to deliver large genetic payloads and support repeat administrations, are pivotal in addressing these unmet medical needs. In addition, their versatility in both in vitro research applications and in vivo therapeutic use cases expands their adoption across biotechnology, pharmaceutical companies, and academic institutes.

The rising government funding and private investments in gene therapy research are also key drivers of market growth. Regions like North America and Europe lead in terms of R&D, but emerging economies in Asia-Pacific, such as China and India, are rapidly advancing due to increasing biotech infrastructure and supportive regulatory frameworks. Furthermore, partnerships between biotech companies and academic institutions are fostering innovation and expanding the accessibility of non-viral delivery solutions, ensuring their relevance in the rapidly evolving field of gene therapy.

Non-viral Gene Delivery Technologies Market Report Highlights:

  • The chemical segment accounted for the largest revenue share in 2024 and is projected to witness the fastest growth rate over the forecast period. The chemical mode of non-viral gene delivery technologies is driven by the increasing demand for efficient, safe, and scalable gene delivery systems.
  • In 2024, research dominated the market with the largest revenue share, driven by the increasing demand for versatile, efficient, and cost-effective tools to investigate gene function, expression, and regulation.
  • By end use, the research and academic institutes segment captured the largest revenue share of 48.11% in 2024 and is expected to experience the fastest CAGR during the forecast period. This growth is fueled by the rising demand for reliable, efficient, and cost-effective approaches to study gene function, expression, and modification.
  • The North American region dominated globally with a market share of 41.25% in 2024. The region benefits from advanced healthcare infrastructure, enabling the rapid adoption of innovative gene delivery techniques. Growing interest in precision medicine and increasing clinical trials focused on genetic disorders further boost market growth. In addition, government initiatives and funding for genomic research contribute to the expanding use of non-viral delivery technologies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Mode Segment
    • 1.1.2. Application Segment
    • 1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Primary Research
  • 1.6. Information or Data Analysis:
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations
  • 1.11. Objective

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Adoption in Therapeutics and Research
      • 3.2.1.2. Technological Advancements and Innovation
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited Delivery Efficiency for Complex Targets
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Mode Business Analysis

  • 4.1. Mode Segment Dashboard
  • 4.2. Non-viral gene delivery technologies market: Mode Movement Analysis
  • 4.3. Non-viral gene delivery technologies market Size & Trend Analysis, by Mode, 2018 to 2030 (USD Million)
  • 4.4. Chemical
    • 4.4.1. Chemical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. LNPs
      • 4.4.2.1. LNPs market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Polymers
      • 4.4.3.1. Polymers market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Physical
    • 4.5.1. Physical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Electroporation
      • 4.5.2.1. Electroporation market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Microinjection
      • 4.5.3.1. Microinjection market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Non-viral gene delivery technologies market Application Movement Analysis
  • 5.3. Non-viral gene delivery technologies market Size & Trend Analysis, by mode, 2018 to 2030 (USD Million)
  • 5.4. Research
    • 5.4.1. Research market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Therapeutics
    • 5.5.1. Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Gene Therapy
      • 5.5.2.1. Gene Therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Cell Therapy
      • 5.5.3.1. Cell Therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.4. Vaccines
      • 5.5.4.1. Vaccines market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Non-viral gene delivery technologies market End Use Movement Analysis
  • 6.3. Non-viral gene delivery technologies market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Biotechnology and Biopharmaceutical Companies
    • 6.4.1. Biotechnology and biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Research and academic institutes
    • 6.5.1. Research and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis by mode, application, end use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecast and Trend Analysis, 2024 & 2030
  • 7.3. North America
    • 7.3.1. North America Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Denmark non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Australia non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Thailand non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. South Korea Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Argentina non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait non-viral gene delivery technologies market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Thermo Fisher Scientific Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. GenScript
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Danaher
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Merck KGaA
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Bio-Rad Laboratories
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Altogen Biosystems
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Lonza
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Sonidel
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. SIRION BIOTECH GmbH
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Innovative Cell Technologies, Inc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global non-viral gene delivery technologies market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 4 Global non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 8 North America Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 9 North America Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 10 U.S. Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 11 U.S. Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 12 U.S. Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 14 Canada Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Canada Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 16 Mexico Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 17 Mexico Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Mexico Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 19 Europe Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 21 Europe Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Europe Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 23 Germany Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 24 Germany Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Germany Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 26 UK Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 27 UK Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 29 France Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 30 France Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 31 France Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 32 Italy Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 33 Italy Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Italy Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 35 Spain Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 36 Spain Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Spain Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 38 Denmark Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 39 Denmark Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 41 Sweden Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 42 Sweden Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Sweden Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 44 Norway Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 45 Norway Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 46 Norway Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 51 China Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 52 China Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 53 China Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 54 Japan Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 55 Japan Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Japan Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 57 India Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 58 India Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 59 India Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 60 South Korea Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 61 South Korea Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 63 Australia Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 64 Australia Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Australia Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 66 Thailand Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 67 Thailand Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Thailand Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 69 Latin America Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 71 Latin America Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Latin America Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 73 Brazil Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 74 Brazil Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 76 Argentina Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 77 Argentina Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 79 Middel East & Africa Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 83 South Africa Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 84 South Africa Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 89 UAE Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 90 UAE Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 91 UAE Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Non-viral gene delivery technologies market: market outlook
  • Fig. 7 Laser capture microdissection competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Non-viral gene delivery technologies market driver impact
  • Fig. 10 Non-viral gene delivery technologies market restraint impact
  • Fig. 11 Non-viral gene delivery technologies market: Mode movement analysis
  • Fig. 12 Non-viral gene delivery technologies market: Mode outlook and key takeaways
  • Fig. 13 Chemical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Physical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 LNPs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Polymers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Electroporation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Microinjection market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Non-viral gene delivery technologies market: Application movement analysis
  • Fig. 22 Non-viral gene delivery technologies market: Application outlook and key takeaways
  • Fig. 23 Research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Gene Therapy market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 26 Cell Therapy market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 27 Vaccines market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 28 Non-viral gene delivery technologies market: End use movement analysis
  • Fig. 29 Non-viral gene delivery technologies market: End use outlook and key takeaways
  • Fig. 30 Biotechnology and biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Research and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 33 North America Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Canada non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Europe non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 UK non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Germany non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Spain non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Norway non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 China non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 India non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Thailand non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Australia non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 UAE Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)